LifeTech Scientific Corporation (HK:1302) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
LifeTech Scientific Corporation has announced the successful completion of a one-year follow-up study for its IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System, showcasing impressive safety and effectiveness results. With a target lesion failure rate of 2.9% and zero cardiac deaths reported, the innovative scaffold is poised for CE registration approval in the European Union. This development promises significant advancements for patients with coronary heart disease worldwide.
For further insights into HK:1302 stock, check out TipRanks’ Stock Analysis page.